We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
IPierian spins off True North and allocates part of $30mm to Series A; Series A disclosed as $22mm
17 Jun 2014
Executive Summary
True North Therapeutics Inc. has spun off from iPierian Inc. to pursue the latter’s monoclonal antibody program targeting the complement pathway. IPierian concurrently received $30mm in financing, most of which will go toward its Series C, with a smaller portion allocated to True North’s Series A round. SR One, Kleiner Perkins Caufield & Byers, and MPM Capital co-led the fundraising, with participation from FinTech Global Capital, Highland Capital Partners, Google Ventures, Mitsubishi UFJ Capital, Biogen Idec New Ventures, and ATEL Ventures. An SR One representative joined both iPierian and True North’s boards.
Deal Industry
Pharmaceuticals
Biotechnology
Large Molecule
Antibodies
Deal Status
Final
Deal Type
Financing
Spin-Off
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?